Exploring Biomarker Analysis, Real-World Data, and Quality of Life in LR-MDS: Insights from EHA 2024
Experts in lower-risk myelodysplastic syndromes analyze and interpret the comparative biomarker data on ring sideroblasts in LR-MDS patients from the COMMANDS study.
Read More
Treatment Decision-Making Based on the COMMANDS Trials
The panel examines the COMMANDS trial results, focusing on luspatercept's effects across erythroid, neutrophil, and platelet lineages and their implications for treatment decisions, while also exploring how genomic factors and mutational burden influence the drug's clinical outcomes in lower-risk myelodysplastic syndromes.
Read More
The aim of this study is to describe the demographic, clinical, and treatment characteristics of patients with LRMDS who were managed by physicians at Florida Cancer Specialists & Research Institute (FCS) and treated with ESAs, and to determine the proportion of LR-MDS patients who experience ESA failure and describe treatment patterns following ESA failure.
Read More
Clinical Implications of COMMANDS Trial in Clinical Practice
The experts examine the COMMANDS trial, which assessed luspatercept in lower-risk myelodysplastic syndrome patients, detailing the trial's design, participant groups, and key outcome measures.
Read More
Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial
A key opinion leader offers insights and analysis on the recently presented COMMANDS trial data from the European Hematology Association 2024 conference.
Read More
The experts examine the COMMANDS trial, which assessed luspatercept in lower-risk myelodysplastic syndrome patients, detailing the trial's design, participant groups, and key outcome measures.
Read More
Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies
The experts describe their strategies for selecting first-line treatments in lower-risk myelodysplastic syndrome patients, focusing on the key factors that inform their sequencing decisions in frontline therapy.
Read More
Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS
Key opinion leaders address various challenges linked to lower-risk myelodysplastic syndromes, with a focus on cytopenias.
Read More
The expert panel in hematology examines recent WHO and ICC guideline updates, evaluating their impact on the evolving treatment landscape for myelodysplastic syndromes.
Read More
Dr Garcia-Manero on the Efficacy of Luspatercept in Transfusion-Dependent MDS
September 9th 2023Guillermo Garcia-Manero, MD, discusses the key efficacy findings from the phase 3 COMMANDS trial evaluating luspatercept-aamt in patients with myelodysplastic syndrome who were erythropoiesis-stimulating agent naïve and red blood cell transfusion dependent.
Read More
Summary of Unmet Needs and Future Directions in MDS
Experts close by summarizing key advances and remaining unmet needs across all MDS risk groups, and share their hopes for the future.
Read More
MDS/MPN-RS-T Overlap Syndromes
A brief discussion centered on MDS/MPN-RS-T overlap syndromes, considerations for diagnosis, available treatment options, and updates in the space.
Read More
Higher-Risk MDS: First- and Second-Line Therapies and Case 3 Presentation/Discussion
The panel turns their focus to higher-risk MDS, starting with a discussion of first- and second-line treatment options, followed by a third and final case presentation and discussion led by Dr Platzbecker.
Read More
Additional Updates in Second-Line Treatment of Lower-Risk MDS
Experts summarize recent updates on other approved or emerging second-line therapies for lower-risk MDS.
Read More
MEDALIST Trial Updates: ASH 2022 and EHA 2022
Dr Komrokji presents key data updates from the MEDALIST trial on luspatercept in patients with lower-risk MDS that were presented at the 2022 European Hematology Association (EHA) Congress and the 2022 ASH Annual Meeting.
Read More
Case 2 Discussion and Considerations for Second-Line Treatment Selection
The panelists discuss Dr Cluzeau’s presented case, emphasizing the importance of pathology reporting, and expand upon approaches to second-line treatment selection for patients with MDS-RS.
Read More
Case 2 Presentation: Lower-Risk MDS-RS With an SF3B1 Mutation
Dr Cluzeau introduces a second patient case of lower-risk MDS-RS with an SF3B1 mutation and symptomatic anemia, who received a first-line erythropoiesis-stimulating agent (ESA) and second-line luspatercept.
Read More
The Impact of p53 Mutations and 5q Deletions on Lower-Risk MDS Treatment Response
Dr Komrokji leads a discussion on emerging data on how p53 mutations and chromosome 5q deletions may affect prognosis, treatment response, and outcomes for patients with MDS.
Read More
Case 1: Expert Panelist Commentary
Expert panelists reflect on the case presented by Dr Garcia-Manero and share their unique perspectives on how they might have approached treatment and followup for this patient in their own practice.
Read More
Case 1 Presentation: Lower-Risk MDS with Multiple Chromosomal Abnormalities
Guillermo Garcia-Manero, MD presents a case of lower-risk MDS with chromosome 5q and 20q deletions and a p53 mutation, and discusses first- and second-line treatment selection.
Read More
Second-Line Treatment Options for Lower-Risk MDS
Dr Platzbecker outlines available second-line therapies for symptomatic anemia in patients with lower-risk MDS, highlighting differences in availability between the United States and Europe.
Read More
First-Line Treatment Options for Lower-Risk MDS
Thomas Cluzeau, MD, PhD provides an overview of first-line treatment options for symptomatic anemia in patients with lower-risk MDS, followed by a discussion of panelists’ treatment patterns and dosing strategies across the globe.
Read More
Considerations for MDS Pathology and Risk Status Reporting
A focused discussion on best practices for MDS pathology and risk status reporting in both community and academic center settings.
Read More
Tools for Risk Stratification and Prognosis in MDS
Uwe Platzbecker, MD introduces models commonly used to determine risk status and prognosis, and inform treatment decisions, for patients with MDS.
Read More
MDS: Typical Patient Presentation, Diagnostic Process, and Evolving Terminology
Moderator Rami Komrokji, MD, introduces the panel and invites expert pathologist Sanam Loghavi, MD to lead a discussion on the typical patient presentation and diagnostic process in MDS, which was recently renamed as ‘myelodysplastic neoplasms’ in the 2022 5th edition of the World Health Organization (WHO) classification of the disease state.
Read More